We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA
Read MoreHide Full Article
GlaxoSmithKline (GSK - Free Report) announced that the FDA accepted its new drug application (NDA) seeking approval of daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for anemia associated with chronic renal disease (CKD). The FDA granted the NDA a standard review and a decision is expected on Feb 1, 2023.
Daprodustat is only approved in Japan as Duvroq for patients with renal anemia. An application seeking the approval of daprodustat for a similar indication is also under review in Europe.
The NDA was based on data from the ASCEND phase III program, which consisted of five studies. All the studies met their primary efficacy and safety endpoints in non-dialysis and dialysis CKD patients. Data from the five phase III studies demonstrated that daprodustat improved or maintained hemoglobin within target levels, without increased cardiovascular risk when compared to the standard of care treatment, an erythropoietin stimulating agent (“ESA”).
Glaxo’s stock has risen 5% this year so far compared with an increase of 7% for the industry.
Image Source: Zacks Investment Research
Anemia is a common complication of CKD. The major cause of anemia in patients with CKD is the decreased ability of kidneys to produce erythropoietin (“EPO”), which leads to insufficient oxygen supply in organs, affecting a person’s quality of life.
Amgen’s (AMGN - Free Report) Epogen and Aranesp and J&J’s (JNJ - Free Report) Procrit/Eprex are popular ESAs used to treat anemia in patients with chronic kidney failure.
Amgen’s ESA franchise, consisting of Epogen and Aranesp, contributed 8% to its 2021 product sales. However, Amgen is seeing declining sales of these drugs due to biosimilar competition.
J&J is also seeing declining sales of Procrit/Eprex due to biosimilar competition.
A better-ranked large drug stock is Eli Lilly (LLY - Free Report) with a Zacks Rank #2 (Buy).
Lilly’s stock has risen 8% this year so far. Estimates for Lilly’s 2022 earnings have gone up from $8.71 to $8.78 while that for 2023 have increased from $9.78 to $9.90 per share over the past 30 days.
Lilly’s earnings performance has been rather weak, with the company missing earnings expectations in each of the last four quarters. Lilly has a four-quarter negative earnings surprise of 3.92%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA
GlaxoSmithKline (GSK - Free Report) announced that the FDA accepted its new drug application (NDA) seeking approval of daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for anemia associated with chronic renal disease (CKD). The FDA granted the NDA a standard review and a decision is expected on Feb 1, 2023.
Daprodustat is only approved in Japan as Duvroq for patients with renal anemia. An application seeking the approval of daprodustat for a similar indication is also under review in Europe.
The NDA was based on data from the ASCEND phase III program, which consisted of five studies. All the studies met their primary efficacy and safety endpoints in non-dialysis and dialysis CKD patients. Data from the five phase III studies demonstrated that daprodustat improved or maintained hemoglobin within target levels, without increased cardiovascular risk when compared to the standard of care treatment, an erythropoietin stimulating agent (“ESA”).
Glaxo’s stock has risen 5% this year so far compared with an increase of 7% for the industry.
Image Source: Zacks Investment Research
Anemia is a common complication of CKD. The major cause of anemia in patients with CKD is the decreased ability of kidneys to produce erythropoietin (“EPO”), which leads to insufficient oxygen supply in organs, affecting a person’s quality of life.
Amgen’s (AMGN - Free Report) Epogen and Aranesp and J&J’s (JNJ - Free Report) Procrit/Eprex are popular ESAs used to treat anemia in patients with chronic kidney failure.
Amgen’s ESA franchise, consisting of Epogen and Aranesp, contributed 8% to its 2021 product sales. However, Amgen is seeing declining sales of these drugs due to biosimilar competition.
J&J is also seeing declining sales of Procrit/Eprex due to biosimilar competition.
Zacks Rank and Stocks to Consider
Glaxo currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A better-ranked large drug stock is Eli Lilly (LLY - Free Report) with a Zacks Rank #2 (Buy).
Lilly’s stock has risen 8% this year so far. Estimates for Lilly’s 2022 earnings have gone up from $8.71 to $8.78 while that for 2023 have increased from $9.78 to $9.90 per share over the past 30 days.
Lilly’s earnings performance has been rather weak, with the company missing earnings expectations in each of the last four quarters. Lilly has a four-quarter negative earnings surprise of 3.92%, on average.